CC 4066
Alternative Names: CC-4066Latest Information Update: 28 Aug 2024
At a glance
- Originator Cypralis Limited
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Cyclophilin D inhibitors; Cyclophilin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Delayed graft function
- No development reported Pancreatitis
Most Recent Events
- 28 Aug 2024 Phase-I clinical trial is ongoing in Delayed graft function (Prevention) (IV) prior to August 2024 (Cypralis pipeline, August 2024)
- 28 Aug 2024 Cypralis completes a phase I trial in Delayed graft function (Prevention) (IV) prior to August 2024 (Cypralis pipeline, August 2024)
- 28 Aug 2024 Cypralis plans a phase II trial in Delayed graft function (Prevention) (IV) in 2022 (Cypralis pipeline, August 2024)